Kestra Medical CEO sells shares to cover taxes

Kestra Medical Technologies, Ltd.'s President and Chief Executive Officer, Brian Daniel Webster, reported selling 51,900 common shares of KMTS on August 4, 2026, across three sale transactions.

Rhea-AI Filing Summary

Kestra Medical Technologies, Ltd.'s President and Chief Executive Officer, Brian Daniel Webster, reported selling 51,900 common shares of KMTS on August 4, 2026, across three sale transactions. Footnotes state these were nondiscretionary sell-to-cover sales to satisfy tax withholding obligations from restricted stock unit vesting, including 48,625 shares at a weighted average price of $24.4692 per share.

Insider Trade Summary

Net Seller: 51,900 shares

Net Sell 3 txns

Insider Webster Brian Daniel

Role See Remarks

Sold 51,900 shs ($1.27M)

Type	Security	Shares	Price	Value
Sale	Common Shares F1, F2	48,625	$24.4692	$1.19M
Sale	Common Shares F1, F3	2,833	$25.1635	$71K
Sale	Common Shares F1, F4	442	$25.9835	$11K

Holdings After Transaction: Common Shares — 475,215 shares (Direct)

Footnotes (4)

1. F1. The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.
2. F2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $23.9000 to $24.8850. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
3. F3. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $24.9500 to $25.9300. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
4. F4. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $25.9500 to $26.0300. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Key Figures

Total shares sold on August 4, 2026: 51,900 common shares First tranche weighted average price: $24.4692 per share Second tranche weighted average price: $25.1635 per share +1 more

4 metrics

Total shares sold on August 4, 2026 51,900 common shares Aggregate KMTS common shares sold by Brian Daniel Webster across three transactions

First tranche weighted average price $24.4692 per share 48,625 KMTS common shares sold on August 4, 2026

Second tranche weighted average price $25.1635 per share 2,833 KMTS common shares sold on August 4, 2026

Third tranche weighted average price $25.9835 per share 442 KMTS common shares sold on August 4, 2026

Key Terms

sell to cover, restricted stock units, weighted average price, tax withholding obligations

4 terms

sell to cover financial

"represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

restricted stock units financial

"tax withholding obligations in connection with the vesting and settlement of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average price financial

"The price in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

tax withholding obligations financial

"sell to cover transactions to satisfy tax withholding obligations in connection with the vesting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Kestra Medical Technologies (KMTS) report in this Form 4?

Kestra Medical Technologies reported that CEO Brian Daniel Webster sold 51,900 common shares of KMTS on August 4, 2026. The Form 4 describes three separate transactions, all involving common shares held directly by Webster as the company’s President and Chief Executive Officer.

How many KMTS shares did Brian Daniel Webster sell in each transaction and at what prices?

Webster sold 48,625 shares at a weighted average price of $24.4692, 2,833 shares at $25.1635, and 442 shares at $25.9835. Each price is reported as a weighted average, with detailed price ranges provided in the Form 4 footnotes.

Why were the KMTS shares sold according to the Form 4 footnotes?

The footnotes state the sales were nondiscretionary “sell to cover” transactions. Shares were required to be sold to satisfy tax withholding obligations arising from the vesting and settlement of restricted stock units granted to Brian Daniel Webster by Kestra Medical Technologies.

What pricing details are disclosed for the KMTS CEO’s share sales?

For each transaction, the Form 4 reports a weighted average price and a price range. The ranges were $23.9000–$24.8850, $24.9500–$25.9300, and $25.9500–$26.0300 per share, with the exact number of shares at each price available on request.

What positions does Brian Daniel Webster hold at Kestra Medical Technologies (KMTS)?

Brian Daniel Webster is identified as both a director and an officer of Kestra Medical Technologies, serving as its President and Chief Executive Officer. These roles are noted in the reporting person information and related remarks section of the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/06/2026 - 06:59 PM Accepted by SEC EDGAR 08/06/2026 - 06:59 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Webster Brian Daniel

(Last) (First) (Middle)

3933 LAKE WASHINGTON BLVD NE, SUITE 200

(Street)

KIRKLAND WASHINGTON 98033

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	08/04/2026		S(1)		48,625	D	$24.4692(2)	478,490	D
Common Shares	08/04/2026		S(1)		2,833	D	$25.1635(3)	475,657	D
Common Shares	08/04/2026		S(1)		442	D	$25.9835(4)	475,215	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.

2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $23.9000 to $24.8850. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

3. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $24.9500 to $25.9300. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

4. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $25.9500 to $26.0300. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Remarks:

President and Chief Executive Officer

	/s/ Brian Daniel Webster	08/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)